Last reviewed · How we verify
Low dose hCG plus FSH co-trigger
Low-dose hCG combined with FSH acts as a dual trigger to induce final oocyte maturation and ovulation in assisted reproductive technology cycles.
Low-dose hCG combined with FSH acts as a dual trigger to induce final oocyte maturation and ovulation in assisted reproductive technology cycles. Used for Final oocyte maturation trigger in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles.
At a glance
| Generic name | Low dose hCG plus FSH co-trigger |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Gonadotropin combination |
| Target | FSH receptor and hCG receptor (LH/hCG receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 3 |
Mechanism of action
This co-trigger strategy uses human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH) together at reduced doses to stimulate the final stages of egg maturation and trigger ovulation. The combination aims to optimize oocyte quality and reduce ovarian hyperstimulation syndrome risk compared to standard hCG-alone triggers, while maintaining efficacy in controlled ovarian hyperstimulation protocols.
Approved indications
- Final oocyte maturation trigger in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Abdominal pain or discomfort
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: